1. Introduction {#sec0005}
===============

In December 2019, some pneumonia cases of unknown origin were identified in Wuhan, the capital city of Hubei province ([@bib0055]; [@bib0060]). The pathogen has been identified as a novel enveloped RNA betacoronavirus that has been named as acute respiratory syndrome coronavirus 2(SARS-Cov-2), which has a phylogenetic similarity to SARS-Cov ([@bib0015]; [@bib0085]; [@bib0165]). The World Health Organization named the disease caused by SARS-Cov-2 as coronavirus disease 2019(COVID-19), and declared it a public health emergency of international concern ([@bib0145], <https://www.who.int>). Although the population is generally susceptible to SARS-CoV-2, most of the patients who need to be admitted to hospital are older ([@bib0155]). And most of deaths are among the elderly ([@bib0125]). Moreover, older age is a potential risk factor for mortality of adult inpatients ([@bib0160]). Although some case series have been published, no previous studies focused on older patients exclusively ([@bib0055]; [@bib0030]; [@bib0100]; [@bib0060]). The estimation of risk factors for severe cases are therefore not very robust. Additionally, details of the clinical course of older patients with COVID-19 have not yet been well described.

Here, we present details of all older patients admitted to the designated hospital in Wuhan---the Sino-French New City Branch of Tongjing Hospital---with laboratory-confirmed COVID-19. We aim to describe clinical, laboratory, and radiological characteristics, treatment, and outcomes of them, and to compare the clinical features between non-severe and severe patients. We hope our finding will call doctors\' attention to older patients with COVID-19.

2. Materials and methods {#sec0010}
========================

2.1. Design {#sec0015}
-----------

We performed a retrospective analysis of hospital admissions for COVID-19 from February 1 st to March 31 st admitted to the Sino-French New City Branch of Tongjing Hospital, one of 53 designated hospitals for COVID-19. The study was approved by the institutional review board of the hospital. Due to the retrospective nature of the study, informed consent was waived.

We included all patients not younger than 65 years old, the data cutoff for the study was March 31 st, 2020. COVID-19 was diagnosed on basis of the WHO interim guidance ([@bib0090]). A confirmed case of COVID-19 was defined as a positive result on high-throughput sequencing or real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. Only laboratory-confirmed cases were included in the analysis.

Enrolled patients were allocated to two groups according to severity of COVID-19 during hospitalization. And we defined the degree of severity of COVID-19 (non-severe vs. severe) using the American Thoracic Society guidelines for community-acquired pneumonia ([@bib0090]).

2.2. Data collection {#sec0020}
--------------------

We extracted the recent exposure history, clinical symptoms or signs, and laboratory findings on admission from electronic medical records. Radiological assessments included chest radiography or computer tomography (CT), and all laboratory testing was performed according to the clinical care needs of the patient. We determined the presence of a radiological abnormality on basis of the documentation or description in medical charts. Laboratory assessments consisted of a complete blood count, blood chemical analysis, coagulation testing, assessment of liver and renal function, and measures of electrolytes, procalcitonin, lactate dehydrogenase, hypersensitive troponin I, creatine kinase, serum ferritin and interleukin-6. All the above data of enrolled patients were recorded with standardized data collection forms.

2.3. Definitions {#sec0025}
----------------

Acute respiratory distress syndrome and shock were defined according to the interim guidance of WHO for novel coronavirus ([@bib0150], <https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>). Hypoxaemia was defined as arterial oxygen tension (PaO~2~) over inspiratory oxygen fraction (FiO~2~) of less than 300 mmHg ([@bib0120]). Acute kidney injury was identified and classified on the basis of the highest serum creatinine level or urine output criteria according to the kidney disease improving global outcomes classification ([@bib0075], <https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf>). Acute cardiac injury was diagnosed if serum levels of cardiac biomarkers (eg, troponin I) were above the 99th percentile upper reference limit, or new abnormalities were shown in electrocardiography and echocardiography ([@bib0130]). Coagulation disorders was defined as a 3-second extension of prothrombin time or a 5-second extension of activated partial thromboplastin time ([@bib0065]). Nosocomial infection was diagnosed if the patients had clinical symptoms or signs of nosocomial pneumonia or bacteraemia, and was combined with a positive culture of a new pathogen from a lower respiratory tract specimen (including the sputum, transtracheal aspirates, or bronchoalveolar lavage fluid, or from blood samples taken≥48 h after admission) ([@bib0035]).

2.4. Statistics {#sec0030}
---------------

Continuous variables were expressed as mean ± SD. Categorical variables were expressed as absolute values and percentages. Paired student's t-test, chi-square, ANOVA and Fisher's exact tests were used to compare values of variables between groups. Bonferroni test was used for correction of multiple testing errors of results from ANOVA. Pearson\'s chi-square test or Fisher\'s exact test were used to assess the association between each of the discrete variables and severe COVID-19. Factors associated with severe COVID-19 in the univariate analysis (p＜0.10) were then included in multivariable regression model. Stepwise selection method for logistic regression model was used to identify the independent risk factors. Statistical tests were considered significant if P \< 0.05. All statistical analyses were performed in SPSS (V.22.0, IBM, Chicago, USA).

3. Results {#sec0035}
==========

312 older inpatients (≥65 years old) were analyzed in the study, and 105 patients were severe cases. The mean age was 69.2 ± 7.3 years, and most patients were male. The mean time from illness onset to hospital admission was 10.4 ± 5.3 days. 148 (47.4 %) patients had exposure history. Comorbidities were present in 241 (77.2 %) patients, with hypertension being the most common, followed by diabetes and cardiovascular disease. The most common symptoms on admission were fever and cough, followed by dyspnea, fatigue and sputum. The mean SOFA and APACHEⅡ score were 3.1 ± 2.2 and 14.3 ± 5.2 separately. The demographics and baseline characteristics of patients on admission were showed in [Table 1](#tbl0005){ref-type="table"} .Table 1Demographics and baseline characteristics of older patients with COVID-19 on admission.Table 1CharacteristicsAll patients (n = 312)Non-severe (n = 207)Severe (n = 105)p valueAge, years69.2 ± 7.367.1 ± 5.471.3 ± 4.60.023Sex(Male/Female)187/125120/8567/400.529Exposure history, n(%)148(47.4)77(37.2)71(67.6)0.039Medication history of ACEI97(31.1)60(29.0)37(35.2)0.053Current smoker, n(%)32(10.3)18(8.70)14(13.3)0.367Co-morbidity, n(%)241(77.2)146(70.5)95(90.5)0.028 Hypertension, n(%)178(57.1)91(44.0)87(82.9)0.017 Diabetes, n(%)121(38.8)72(34.8)49(46.7)0.045 Cardiovascular disease, n(%)93(29.8)47(22.7)46(43.8)0.025 Chronic lung disease, n(%)27(8.65)16(7.73)11(10.5)0.035 Cerebrovascular disease, n(%)20(6.41)11(5.31)9(8.57)0.617 Chronic liver disease, n(%)11(3.53)7(3.38)4(3.81)0.801 Chronic kidney disease, n(%)10(3.21)6(2.90)4(3.81)0.549 Tumour, n(%)12(3.85)7(3.38)5(4.71)0.587Fever(temperature＞37℃), n(%)252(80.8)170(82.1)82(78.1)0.125Respiratory rate ＞24 breaths per min, n(%)101(32.4)51(24.6)50(47.6)0.037Pulse ≥ 125 beats per min, n(%)13(4.17)4(1.93)9(8.82)0.012Systolic pressure, mmHg120.3 ± 30.3135.4 ± 27.6112.5 ± 35.70.031Headache, n(%)28(8.97)17(8.21)11(10.5)0.419Cough, n(%)239(76.6)155(74.9)84(80.0)0.603Sputum, n(%)67(21.5)42(20.3)25(23.8)0.568Nausea or vomiting, n(%)22(7.05)13(6.28)9(8.57)0.246Diarrhoea, n(%)25(8.01)17(8.21)8(7.62)0.086Myalgia, n(%)18(5.77)10(4.83)8(7.62)0.063Fatigue, n(%)83(26.6)40(19.3)43(41.0)0.015Dyspnea, n(%)167(53.5)84(40.6)83(79.0)0.021Chills, n(%)33(10.6)11(5.31)22(21.0)0.013Time from illness onset to hospital admission, days10.4 ± 5.310.1 ± 6.710.6 ± 5.10.521IADL0.85 ± 0.230.96 ± 0.120.81 ± 0.210.531SOFA score3.1 ± 2.22.5 ± 2.34.3 ± 2.50.003APACHEⅡ score14.3 ± 5.212.1 ± 5.616.3 ± 4.30.002[^1]

The white blood cell count, d-dimer, transaminase, bilirubin and creatinine were significantly higher in severe cases than non-severe cases. But the lymphocyte count and platelet count were significantly lower. From the perspective of inflammation indicators, procalcitonin, serum ferritin and interleukin-6 were much higher in severe cases. As for radiological findings, consolidation and bilateral pulmonary infiltration were found in 88.7 % and 71.4 % of severe patients, which were significantly higher than non-severe patients. The laboratory and radiographic findings of patients on admission were showed in [Table 2](#tbl0010){ref-type="table"} .Table 2Laboratory and radiographic findings of older patients with COVID-19 on admission.Table 2All patients (n = 312)Non-severe (n = 207)Severe (n = 105)p valueWhite blood cell count, ×10^9^/L7.5 ± 4.36.8 ± 3.912.1 ± 4.50.031Neutrophil count, ×10^9^/L6.1 ± 3.65.7 ± 3.510.3 ± 5.10.039Lymphocyte count, ×10^9^/L1.1 ± 0.41.9 ± 0.60.8 ± 0.40.012 ＜1.1, n(%)191(61.2)109(52.7)82(78.1)0.029Haemoglobin, g/L120.3 ± 28.4124.5 ± 32.1119.4 ± 25.70.387Platelet count, ×10^9^/L205.3 ± 85.6233.7 ± 92.6157.4 ± 95.30.002 ＜125, n(%)64(20.5)10(4.83)54(51.4)0.001Prothrombin time, s13.5 ± 4.912.7 ± 5.414.8 ± 4.50.010Activated partial thromboplastin time, s35.4 ± 6.333.9 ± 5.638.7 ± 7.80.028D-dimer, mg/L0.7 ± 0.60.5 ± 0.34.8 ± 2.10.018Alanine transaminase, U/L40.5 ± 20.531.6 ± 18.948.2 ± 20.10.009Aspartate transaminase, U/L45.2 ± 30.640.6 ± 22.750.3 ± 29.80.005Total bilirubin, mmol/L18.7 ± 10.513.7 ± 9.921.2 ± 9.60.035Creatinine, μmol/L64.7 ± 46.752.4 ± 40.291.3 ± 41.30.003 ＞133, n(%)21(6.73)4(1.93)17(16.2)0.016Potassium, mmol/L4.0 ± 1.13.9 ± 0.84.2 ± 1.00.535Sodium, mmol/L141.1 ± 9.2143.0 ± 8.3139.8 ± 7.90.457Creatine kinase, U/L85.6 ± 46.782.3 ± 38.7101.2 ± 32.10.612Lactate dehydrogenase, U/L200.2 ± 61.2150.4 ± 58.4220.1 ± 42.10.652Hypersensitive troponin I, pg/mL8.6 ± 4.37.5 ± 5.415.3 ± 3.60.025Procalcitonin, ng/mL0.25 ± 0.120.16 ± 0.110.33 ± 0.200.013Serum ferritin, μg/L702.3 ± 200.4665.4 ± 86.51203.1 ± 126.70.027Interleukin-6, pg/mL7.8 ± 4.66.9 ± 3.818.7 ± 4.50.001Ground-glass opacity, n(%)251(80.4)170(82.1)81(77.1)0.052Consolidation, n(%)163(52.2)70(43.5)93(88.6)0.005Bilateral pulmonary infiltration, n(%)231(74.0)156(50.0)75(71.4)0.042

Further regression analysis suggested that age(OR 1.59, 95 %CI 1.13−2.08), SOFA score(OR 5.89, 95 %CI 3.48−7.96), APACHEⅡ score(OR 3.13, 95 %CI 1.85−5.62), platelet count＜125 × 10^9^/L(OR 2.36, 95 %CI 1.03−4.14), d-dimer(OR 4.37, 95 %CI 2.58−7.16), creatinine＞133 μmol/L(OR 1.85, 95 %CI 1.12−3.04), interleukin-6(OR 4.32, 95 %CI 2.07−7.13), and lung consolidation(OR 1.94, 95 %CI 1.45−4.27) on admission were independent risk factors for severe COVID-19 ([Table 3](#tbl0015){ref-type="table"} ).Table 3The risk factors associated with severe COVID-19 in older patients.Table 3Risk factorsBSEWaldp valueOR95 %CIAge0.0750.04710.2640.01021.591.13−2.08SOFA score0.0940.05724.167\<0.00015.893.48−7.96APACHEⅡ score1.0030.3643.7850.00183.131.85−5.62Platelet count＜125 × 10^9^/L0.1380.0494.6820.01282.361.03−4.14D-dimer0.0360.4976.1480.00244.372.58−7.16Creatinine＞133 μmol/L0.0170.2182.1940.01371.851.12−3.04Interleukin-60.2450.4167.3780.00164.322.07−7.13Consolidation0.3390.6753.5690.02621.941.45−4.27[^2]

The most common complication was acute respiratory distress syndrome (35.6 %), followed by acute cardiac injury (33.0 %) and coagulation disorders (30.8 %). 91.7 % of patients were prescribed antiviral therapy, followed by immune globulin (52.9 %) and systemic glucocorticoids (43.6 %). 21.8 % of patients received invasive ventilation, 1.92 % for extracorporeal membrane oxygenation. The overall mortality was 6.73 %, and mortality of severe patients was 17.1 %, which was higher than non-severe patients (0.962 %). The complications, treatments and outcomes of patients were showed in [Table 4](#tbl0020){ref-type="table"} .Table 4Complications, treatments and outcomes of older patients with COVID-19.Table 4All patients (n = 312)Non-severe (n = 207)Severe (n = 105)p value**Complications** Acute respiratory distress syndrome, n(%)111(35.6)18(8.70)93(88.6)0.041 Shock, n(%)76(24.4)10(4.83)66(62.9)0.027 Acute kidney injury, n(%)50(16.0)7(3.38)43(41.0)0.004 Acute cardiac injury, n(%)103(33.0)37(17.9)66(62.9)0.038 Coagulation disorders, n(%)96(30.8)66(31.9)30(28.6)0.645 Nosocomial infection, n(%)18(5.77)4(1.93)14(13.3)0.009**Treatments** Antiviral therapy, n(%)286(91.7)186(89.9)100(95.2)0.426 Antibacterial therapy, n(%)87(27.9)16(15.2)71(67.6)0.031 Systemic glucocorticoids, n(%)136(43.6)68(32.9)68(64.8)0.046 Immune globulin, n(%)165(52.9)70(33.8)95(90.5)0.035 High-flow nasal cannula, n(%)94(30.1)83(40.1)11(10.5)0.029 Noninvasive ventilation, n(%)22(7.05)2(0.966)20(19.0)\<0.001 Invasive ventilation, n(%)68(21.8)068(64.8)\<0.001 Extracorporeal membrane oxygenation, n(%)6(1.92)06(5.71)\<0.001 Continuous renal replacement therapy, n(%)24(7.69)024(22.9)\<0.001**Outcomes**0.010 Discharge, n(%)245(78.5)193(93.2)52(49.5) Hospitalization, n(%)46(14.7)11(5.31)35(33.3) Death, n(%)21(6.73)3(0.962)18(17.1)

4. Discussion {#sec0040}
=============

To our knowledge, this retrospective study was the first case series focusing on hospitalized older patients (≥65 years) with COVID-19 exclusively. By March 31 st 2020, 312 patients were recruited in the Sino-French New City Branch of Tongjing Hospital, which was designated to treat COVID-19 patients in Wuhan, China. This study compared clinical characteristics between non-severe and severe COVID-19 cases among older patients, and identified several risk factors for severe cases.

Older patients had more previous medical history, so there were more comorbidities ([@bib0080]). Hypertension and diabetes were common among Chinese elderly ([@bib0040]). Cardiovascular disease had a high comorbidity rate, which may be related to the characteristics of the SARS-Cov-2 ([@bib0020]). Angiotensin-converting enzyme 2 (ACE2) was also highly expressed in myocardium, which was the main target of SARS-CoV-2 attack ([@bib0050]). The main clinical manifestations included fever, cough, dyspnea, fatigue, which were inconsistent with the clinical manifestations reported in the previous literature ([@bib0025]). This meant that older patients had their own characteristics. The proportion of older patients with dyspnea was higher than previous studies, which may be related to poor compensation of respiratory function in the elderly ([@bib0025]). The elderly were inherently susceptible to fatigue ([@bib0140]). Coupled with the effects of hypoxia, the proportion of older patients with fatigue was also higher than the overall population. Like other studies, the rate of older patients with nausea, vomiting or diarrhea was not high ([@bib0025]). Therefore, part of the gastrointestinal symptoms encountered in the clinic may be side effects of drug treatment. SOFA and APACHEⅡ score were tools that reflected the severity of the illness, with good sensitivity and specificity ([@bib0045]; [@bib0110]). The scores of elderly COVID-19 patients was significantly higher than other diseases, especially in severe cases. In addition, severe cases were significantly different from non-severe cases in terms of age, comorbidities, and symptoms.

Similar to previous studies among patients of all ages, important laboratory findings in older patients included low lymphocyte and platelet counts, elevated coagulation time, d-dimer, transaminase, bilirubin and creatinine ([@bib0030]). As compared with overall population, older patients had higher percentages with above abnormalities, and the severe cases had much higher percentages. SARS-CoV-2 can attack cardiomyocytes trough binding to ACE2 receptors on Cardiomyocyte membrane ([@bib0050]). So the hypersensitive troponin I was high. And severe cases were higher than non-severe. Essentially, COVID-19 was an infectious disease caused by a virus, so it could cause an inflammatory response ([@bib0070]). The procalcitonin, serum ferritin and interleukin-6 would rise. The more severe the COVID-19, the higher the degree of increase. The lung was the most severe organ involved in COVID-19. The most findings of lung CT were ground-glass opacity, bilateral pulmonary infiltration and consolidation, which were similar to previous studies ([@bib0005]). Similarly, severe cases were much worse from non-severe cases in terms of laboratory and radiographic abnormalities.

This study identified several risk factors for severe COVID-19 cases among older patients. In general, older age, higher SOFA and APACHEⅡscore, platelet count＜125 × 10^9^/L, creatinine＞133 μmol/L, higher interleukin-6 and d-dimer, and lung consolidation on admission were associated with higher odds of severe COVID-19. There may be overlapping indicators between these factors. For example, platelet count＜125 × 10^9^/L and creatinine＞133 μmol/L were items of SOFA and APACHEⅡscore, which meant coagulation and kidney dysfunction ([@bib0110]). Previous studies in macaques inoculated with SARS-CoV found that older macaques had stronger host innate response to virus infection, with increase in expression of genes associated with inflammation ([@bib0135]). The age-dependent defects in T-cell an B-cell function and the excess production of type 2 cytokines could lead to a deficiency in control of viral replication and more prolonged proinflammatory responses, potentially leading to severe cases ([@bib0105]). Currently, there was no scale specifically for COVID-19. SOFA and APACHEⅡscore were commonly used in intensive care unite, which reflected the state and degree of multi-organ dysfunction. The higher the score, the more serious the illness. High levels of d-dimer had a reported association with pneumonia severity in emergency department, which also applied to older COVID-19 patients.

Like the SARS and MERS, the most common complication was acute respiratory distress syndrome, owing to direct injury of SARS-CoV-2 and secondary injury of inflammation ([@bib0115]). Injury of vascular endothelium and hematopoietic function by viral toxins and inflammatory factors caused coagulation disorders ([@bib0065]). So far, there were no effective antiviral drugs for SARS-CoV-2. But Chines doctors often prescribed antiviral drugs empirically or according to the consensus of Chinese experts. Immune globulin and systemic glucocorticoids were also suggested by consensus of Chinese experts. As with the treatment of hypoxemia caused by other causes, the methods of oxygen therapy included high-flow nasal cannula, noninvasive ventilation, Invasive ventilation, and extracorporeal membrane oxygenation. The more severe the condition, the greater the intensity of support required. But patients' resilience were ignored in the treatment in China ([@bib0010]). The overall mortality was 6.73 % for older patients, which was higher than previous studies. One of the main reasons was the poor compensatory function of multiple organs in the elderly. But mortality was similar to another Chinese study ([@bib0095]).

There are some limitations in the present study. First, it was a single-center study. The hospital for treating patients with COVID-19 was designated by government. And admitted patients were also designated by the government. So there must be some selective bias. Second, as of March 31 st, there were still some patients in hospital. Their prognosis can not be determined. Hence, more future studies need to be carried out to further clarify these issues.

In summary, Older patients with COVID-19 had much more co-morbidity, complications and mortality. Age, SOFA score, APACHEⅡ score, platelet count＜125 × 109/L, d-dimer, creatinine＞133 μmol/L, interleukin-6, and lung consolidation on admission were independent risk factors for severe cases among older patients with COVID-19. For clinical practice, more attention should be paid to older patients with COVID-19.
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[^1]: Abbreviations: ACEI, Anti-angiotensin-Converting Enzyme Inhibitor; IADL, Instrumental Activities of Daily Living; SOFA, Sequential Organ Failure Assessment; APACHE, Acute Physiologic and Chronic Health Evaluation.

[^2]: Abbreviations: SOFA, Sequential Organ Failure Assessment; APACHE, Acute Physiologic and Chronic Health Evaluation.
